Dr. Lal Path Labs Ltd. — Updates, 25-04-2025: Press Release

Dr. Lal PathLabs Limited reported a strong performance in Q4 FY 2024-25, with revenue reaching ₹603 Cr, marking a 10.5% increase compared to the same quarter last year. The company's EBITDA rose by 16.9%, achieving a margin of 28.1%. Impressively, profit after tax (PAT) surged by 81.4%, resulting in a PAT margin of 25.8%. As a gesture to shareholders, the company announced a fourth interim dividend of ₹6 per share for FY25.

With a robust network of 298 clinical laboratories, 6,607 patient service centers, and 12,365 pick-up points, Dr. Lal PathLabs is well-positioned in the diagnostic healthcare sector. The company's operational expansion and impressive financial growth suggest a positive outlook for future performance, making it a key player in India's healthcare landscape. Investors should watch closely for continued momentum in revenue and profit growth as the company navigates an evolving market.